Mirae Asset Global Investments Co., Ltd. Syndax Pharmaceuticals Inc Transaction History

Mirae Asset Global Investments Co., Ltd.

$22.5 Billion
Q3 2024

A detailed history of Mirae Asset Global Investments Co., Ltd. transactions in Syndax Pharmaceuticals Inc stock. As of the latest transaction made, Mirae Asset Global Investments Co., Ltd. holds 3,078 shares of SNDX stock, worth $66,238. This represents 0.0% of its overall portfolio holdings.

Number of Shares

3,078

Previous 2,537 21.32%

Holding current value

$66,238

Previous $52,000 13.46%

% of portfolio

0.0%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 23, 2024	BUY	$17.93 - $24.81 $9,700 - $13,422	541 Added 21.32%	3,078 $59,000
Q2 2024 Jul 30, 2024	SELL	$18.82 - $23.79 $710,097 - $897,620	-37,731 Reduced 93.7%	2,537 $52,000
Q1 2024 May 01, 2024	SELL	$19.71 - $24.57 $130,657 - $162,874	-6,629 Reduced 14.14%	40,268 $958,000
Q4 2023 Jan 24, 2024	BUY	$11.39 - $21.67 $53,589 - $101,957	4,705 Added 11.15%	46,897 $1.01 Million
Q3 2023 Oct 26, 2023	BUY	$14.52 - $21.77 $39,204 - $58,779	2,700 Added 6.84%	42,192 $612,000
Q2 2023 Aug 10, 2023	BUY	$19.35 - $22.31 $11,900 - $13,720	615 Added 1.58%	39,492 $826,000
Q1 2023 May 04, 2023	BUY	$20.66 - $28.98 $277,463 - $389,201	13,430 Added 52.78%	38,877 $821,000
Q4 2022 Feb 09, 2023	BUY	$20.64 - $26.24 $40,392 - $51,351	1,957 Added 8.33%	25,447 $647,000
Q3 2022 Nov 10, 2022	BUY	$18.51 - $24.79 $134,290 - $179,851	7,255 Added 44.69%	23,490 $565,000
Q2 2022 Jul 26, 2022	BUY	$13.64 - $19.48 $221,445 - $316,257	16,235 New	16,235 $313,000

Others Institutions Holding SNDX

# of Institutions

203

Shares Held

87.6M

Call Options Held

268K

Put Options Held

76.8K

View Full List

About Syndax Pharmaceuticals Inc

Ticker SNDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,565,200
Market Cap $1.22B
Description
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...

More about SNDX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Mirae Asset Global Investments Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Mirae Asset Global Investments Co., Ltd. with notifications on news.

Account

Mirae Asset Global Investments Co., Ltd. Syndax Pharmaceuticals Inc Transaction History